Orion (ORNBV) CMD 2025 summary

Strategic direction and growth plans

• Achieved €1.5 billion net sales target ahead of schedule in 2024, with a 27% operating margin and €470 million profit.

• Strategy centers on innovation, geographic expansion (Japan, US, UK, India, China, APAC, Europe), and portfolio diversification, focusing on oncology, pain, and value-added generics.

• All business divisions contribute, with investments in R&D, sustainability, and mastering the end-to-end value chain.

• Acquisitions, in-licensing, and strategic partnerships are considered to complement organic growth and expand capabilities.

• Building commercial and R&D capabilities globally, including new hubs in the US and UK.

Financial guidance and capital allocation

• Mid-term objectives (2024–2028): net sales CAGR ≥8%, operating profit to outpace sales, equity ratio ≥50%, return on equity >25%.

• Dividend policy targets annual increases with a payout ratio of 50–100%.

• R&D spend historically 10–12% of net sales, with CapEx at 4–5%; potential to rise if clinical pipeline advances.

• Revenue targeted to grow from EUR 1.5B to EUR 2B by 2028, supported by increased R&D and CapEx investments.

• Ample M&A firepower, with up to €2 billion capacity for acquisitions, focusing on strategic fit in current and new markets.

Business division updates and growth drivers

• Innovative medicines: Nubeqa (darolutamide) and opevesostat drive growth, with label expansions and new indications expected; robust pipeline includes ODM-105 (insomnia), ODM-212 (oncology), and upcoming biologics ODM-214, ODM-215, ODM-216.

• Branded products: Easyhaler respiratory portfolio and Parkinson’s Disease treatments are central, with Easyhaler sales targeted to exceed EUR 300M, supported by environmental trends and market expansion.

• Generics and consumer health: Portfolio transformation toward complex and value-adding generics, new sales channels, and expansion in Europe’s Big5, Scandinavia, and Poland.

• Animal health: Integration of recent acquisitions, global presence, and focus on innovation, customer loyalty, and new product launches in both companion animal and livestock segments.

• Launching direct-to-consumer online store in Sweden and piloting new digital sales channels to accelerate consumer health growth.